Vaccine News and Research RSS Feed - Vaccine News and Research

A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters.
ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

ITS develops new T cell vaccine to protect humans from seasonal and pandemic influenza A

Immune Targeting Systems, specializing in the development of novel T cell immune therapies, has been developing an exciting new T cell vaccine (FlunisynTM) designed to protect humans from all strains of seasonal and pandemic influenza A. [More]
61% of U.S. adults unaware of the importance of high dose flu vaccine in flu prevention for older adults

61% of U.S. adults unaware of the importance of high dose flu vaccine in flu prevention for older adults

A new survey from CVS/pharmacy released today found that three in five U.S. adults (61 percent) are unaware of the importance of the high dose flu vaccine in flu prevention for adults 65 years and older. [More]
WHO taps UTMB to lead emerging infectious disease vaccine efforts

WHO taps UTMB to lead emerging infectious disease vaccine efforts

The world experts on vaccine development at the University of Texas Medical Branch at Galveston have received an international designation acknowledging their unique niche in a sphere where research, government regulation and big pharma often collide. [More]
Medical advisory panel recommends new pneumonia vaccine for seniors

Medical advisory panel recommends new pneumonia vaccine for seniors

The experts expressed concern, however, that Medicare rules may hamper some people from getting the new vaccine if they have already had an older version. Also in drug issues, some patient advocates report that insurers are balking at paying for a costly drug to treat hepatitis C if the patients are in drug treatment programs. [More]
Scientists identify gene that regulates sleep and wake rhythms

Scientists identify gene that regulates sleep and wake rhythms

Scientists at the Salk Institute for Biological Studies have identified a gene that regulates sleep and wake rhythms. [More]
Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Microbiologist receives contract from U.S. DOD to develop vaccine against tularemia

Microbiologist Karl Klose, a professor in the UTSA College of Sciences' Department of Biology and a member of the South Texas Center for Emerging Infectious Diseases, has received a contract from the U.S. Department of Defense (DOD) to conduct research that would bring scholars one step closer to developing a vaccine against tularemia. [More]
Research and planning to meet health needs of people living with HIV

Research and planning to meet health needs of people living with HIV

As effective treatments for HIV become more widely available in low- and middle-income countries, there's an urgent need to assess and manage health risks in the growing number of people living with HIV. [More]
MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX begins phase I clinical trial for proprietary cancer vaccine platform

MicroVAX, LLC, a biotech company located in Manassas, Virginia announced today the commencement of a phase I clinical trial for its unique and proprietary vaccine platform that allows under the provisions of an FDA IND entry of patients with cancers of the, breast, prostate, colon, ovary and lung, that have relapsed after initial salvage therapy. [More]
High-dose influenza vaccine 24% more effective in older adults

High-dose influenza vaccine 24% more effective in older adults

High-dose influenza vaccine is 24 percent more effective than the standard-dose vaccine in protecting persons ages 65 and over against influenza illness and its complications, according to a Vanderbilt-led study published today in the New England Journal of Medicine. [More]
Canadian government to donate experimental vaccine to combat Ebola virus

Canadian government to donate experimental vaccine to combat Ebola virus

The Honourable Rona Ambrose, Minister of Health, today announced that the Government of Canada will donate doses of an experimental Ebola vaccine developed by the Public Health Agency of Canada to the World Health Organization (WHO) in its role as an international coordinating body in responding to the ongoing Ebola outbreak in West Africa. [More]
Plan International outlines strategies to combat Ebola outbreak

Plan International outlines strategies to combat Ebola outbreak

The current Ebola outbreak, the most severe and complex in history, is now making its impact felt worldwide. [More]
Injecting vaccine-like compound into mice effective in protecting from malaria

Injecting vaccine-like compound into mice effective in protecting from malaria

A study led by Johns Hopkins Bloomberg School of Public Health researchers found that injecting a vaccine-like compound into mice was effective in protecting them from malaria. [More]
New approach to knocking out parasite's genes

New approach to knocking out parasite's genes

Plasmodium falciparum, the parasite that causes malaria, has proven notoriously resistant to scientists' efforts to study its genetics. [More]
Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals reports increased revenue in second quarter 2014

Inovio Pharmaceuticals, Inc. today reported financial results for the quarter ended June 30, 2014. Total revenue was $3.8 million and $6.2 million for the three and six months ended June 30, 2014, compared to $786,000 and $2.2 million for the same periods in 2013. [More]
Alexza Pharmaceuticals announces availability of ADASUVE inhalation powder in Guatemala

Alexza Pharmaceuticals announces availability of ADASUVE inhalation powder in Guatemala

Alexza Pharmaceuticals, Inc. today announced that ADASUVE inhalation powder, pre-dispensed (loxapine) is now available in Guatemala. This approval represents the first ADASUVE approval in Latin America for Ferrer and Alexza. [More]
New method of growing human cells may help develop tailor-made therapies for GI conditions

New method of growing human cells may help develop tailor-made therapies for GI conditions

A method of growing human cells from tissue removed from a patient's gastrointestinal (GI) tract eventually may help scientists develop tailor-made therapies for inflammatory bowel disease and other GI conditions. [More]
Viewpoints: Why Emory accepted American Ebola cases; calls for terrified Americans to 'chill out'

Viewpoints: Why Emory accepted American Ebola cases; calls for terrified Americans to 'chill out'

Blame it on Richard Preston. "The Hot Zone," his 1994 nonfiction science thriller about the spread and devastation of the Ebola virus, pretty much set the standard for terrifying contagion scenarios. ... [More]
Many hospitals struggle to meet electronic health records deadline and face penalties

Many hospitals struggle to meet electronic health records deadline and face penalties

Many of the nation's hospitals struggled to meet a federally mandated electronic health records deadline, and as a result could collectively face millions of dollars in reduced Medicare payments this year, a University of Michigan study shows. [More]
Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix demonstrates improved immunogenicity and rapid action of anthrax vaccine, VeloThrax

Soligenix, Inc., a clinical stage biopharmaceutical company focused on developing products to treat serious inflammatory diseases where there remains an unmet medical need, as well as developing several biodefense vaccines and therapeutics, announced today results demonstrating the improved immunogenicity and rapid action of its anthrax vaccine, VeloThrax™. [More]
Researchers plan to develop vaccine into a type of antibody serum therapy

Researchers plan to develop vaccine into a type of antibody serum therapy

By many estimates, an Ebola vaccine could be available in humans as early as next year. But will it be the right one? There are a number of vaccines in development and each is in a race to prove that it is most effective, safe and that it will protect the largest number of people. [More]